Log in

Relevant bibliographies by topics / Ligase I Inhibitors

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Ligase I Inhibitors'

Author: Grafiati

Published: 6 September 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Ligase I Inhibitors.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Ligase I Inhibitors"

1

Alomari, Arqam, Robert Gowland, Callum Southwood, et al. "Identification of Novel Inhibitors of Escherichia coli DNA Ligase (LigA)." Molecules 26, no. 9 (2021): 2508. http://dx.doi.org/10.3390/molecules26092508.

Full text

Abstract:

Present in all organisms, DNA ligases catalyse the formation of a phosphodiester bond between a 3′ hydroxyl and a 5′ phosphate, a reaction that is essential for maintaining genome integrity during replication and repair. Eubacterial DNA ligases use NAD+ as a cofactor and possess low sequence and structural homology relative to eukaryotic DNA ligases which use ATP as a cofactor. These key differences enable specific targeting of bacterial DNA ligases as an antibacterial strategy. In this study, four small molecule accessible sites within functionally important regions of Escherichia coli ligase

APA, Harvard, Vancouver, ISO, and other styles

2

Ciarrocchi, Giovanni, Donald G. MacPhee, Les W. Deady, and Leann Tilley. "Specific Inhibition of the Eubacterial DNA Ligase by Arylamino Compounds." Antimicrobial Agents and Chemotherapy 43, no. 11 (1999): 2766–72. http://dx.doi.org/10.1128/aac.43.11.2766.

Full text

Abstract:

ABSTRACT All known DNA ligases catalyze the formation of a phosphodiester linkage between adjacent termini in double-stranded DNA via very similar mechanisms. The ligase family can, however, be divided into two classes: eubacterial ligases, which require NAD+ as a cofactor, and other ligases, from viruses, archaea, and eukaryotes, which use ATP. Drugs that discriminate between DNA ligases from different sources may have antieubacterial activity. We now report that a group of arylamino compounds, including some commonly used antimalarial and anti-inflammatory drugs and a novel series of bisquin

APA, Harvard, Vancouver, ISO, and other styles

3

Lama, Rati, Samuel L. Galster, Chao Xu, Luke W. Davison, Sherry R. Chemler, and Xinjiang Wang. "Dual Targeting of MDM4 and FTH1 by MMRi71 for Induced Protein Degradation and p53-Independent Apoptosis in Leukemia Cells." Molecules 27, no. 22 (2022): 7665. http://dx.doi.org/10.3390/molecules27227665.

Full text

Abstract:

MDM2 and MDM4 are cancer drug targets validated in multiple models for p53-based cancer therapies. The RING domains of MDM2 and non-p53-binder MDM2 splice isoforms form RING domain heterodimer polyubiquitin E3 ligases with MDM4, which regulate p53 stability in vivo and promote tumorigenesis independent of p53. Despite the importance of the MDM2 RING domain in p53 regulation and cancer development, small molecule inhibitors targeting the E3 ligase activity of MDM2-MDM4 are poorly explored. Here, we describe the synthesis and characterization of quinolinol derivatives for the identification of a

APA, Harvard, Vancouver, ISO, and other styles

4

Shapiro, Adam B., Ann E. Eakin, Grant K. Walkup, and Olga Rivin. "A High-Throughput Fluorescence Resonance Energy Transfer-Based Assay for DNA Ligase." Journal of Biomolecular Screening 16, no. 5 (2011): 486–93. http://dx.doi.org/10.1177/1087057111398295.

Full text

Abstract:

DNA ligase is the enzyme that catalyzes the formation of the backbone phosphodiester bond between the 5′-PO4 and 3′-OH of adjacent DNA nucleotides at single-stranded nicks. These nicks occur between Okazaki fragments during replication of the lagging strand of the DNA as well as during DNA repair and recombination. As essential enzymes for DNA replication, the NAD+-dependent DNA ligases of pathogenic bacteria are potential targets for the development of antibacterial drugs. For the purposes of drug discovery, a high-throughput assay for DNA ligase activity is invaluable. This article describes

APA, Harvard, Vancouver, ISO, and other styles

5

Gorelik, Maryna, Stephen Orlicky, Maria A. Sartori, et al. "Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1–F-box interface." Proceedings of the National Academy of Sciences 113, no. 13 (2016): 3527–32. http://dx.doi.org/10.1073/pnas.1519389113.

Full text

Abstract:

Skp1–Cul1–F-box (SCF) E3 ligases play key roles in multiple cellular processes through ubiquitination and subsequent degradation of substrate proteins. Although Skp1 and Cul1 are invariant components of all SCF complexes, the 69 different human F-box proteins are variable substrate binding modules that determine specificity. SCF E3 ligases are activated in many cancers and inhibitors could have therapeutic potential. Here, we used phage display to develop specific ubiquitin-based inhibitors against two F-box proteins, Fbw7 and Fbw11. Unexpectedly, the ubiquitin variants bind at the interface o

APA, Harvard, Vancouver, ISO, and other styles

6

Marblestone, Jeffrey G., K. G. Suresh Kumar, Michael J. Eddins, et al. "Novel Approach for Characterizing Ubiquitin E3 Ligase Function." Journal of Biomolecular Screening 15, no. 10 (2010): 1220–28. http://dx.doi.org/10.1177/1087057110380456.

Full text

Abstract:

The ubiquitin-proteasome system is central to the regulation of numerous cellular events, and dysregulation may lead to disease pathogenesis. E3 ubiquitin ligases typically function in concert with E1 and E2 enzymes to recruit specific substrates, thereby coordinating their ubiquitylation and subsequent proteasomal degradation or cellular activity. E3 ligases have been implicated in a wide range of pathologies, and monitoring their activity in a rapid and cost-effective manner would be advantageous in drug discovery. The relative lack of high-throughput screening (HTS)–compliant E3 ligase assa

APA, Harvard, Vancouver, ISO, and other styles

7

Tobin, Lisa A., Aaron P. Rapoport, Ivana Gojo, Maria R. Baer, Alan E. Tomkinson, and Feyruz V. Rassool. "DNA Ligase III Alpha and (Poly-ADP) Ribose Polymerase (PARP1) Are Therapeutic Targets in Imatinib-Resistant (IR) Chronic Myeloid Leukemia (CML)." Blood 114, no. 22 (2009): 853. http://dx.doi.org/10.1182/blood.v114.22.853.853.

Full text

Abstract:

Abstract Abstract 853 Therapy with the tyrosine kinase inhibitor imatinib, targeting the constitutively active BCR-ABL kinase has been remarkably successful in Philadelphia chromosome-positive (Ph+) CML, but resistance to tyrosine kinase inhibitors is a growing clinical problem, prompting the search for new therapeutic targets. BCR-ABL expression leads to increased reactive oxygen species (ROS), repair errors and genomic instability. We have previously shown that an error-prone alternative non-homologous end-joining (ALT NHEJ) pathway involving PARP1 and DNA ligase IIIa/XRCC1 is upregulated in

APA, Harvard, Vancouver, ISO, and other styles

8

TAN, Ghee T., Sangkook LEE, Ik-Soo LEE, et al. "Natural-product inhibitors of human DNA ligase I." Biochemical Journal 314, no. 3 (1996): 993–1000. http://dx.doi.org/10.1042/bj3140993.

Full text

Abstract:

Enzymic activity mediated by recombinant human DNA ligase I (hLI), in conjunction with tannin removal procedures, has been applied to a natural-product screen involving ~1000 plant extracts and various pure compounds. The primary hLI activity assay involved the measurement of the amount of radiolabelled phosphate in a synthetic nucleic acid hybrid that becomes resistant to alkaline phosphatase as a result of ligation. A bioactivity-guided fractionation scheme resulted in the isolation of ursolic [IC50 = 100 μg/ml (216 μM)] and oleanolic [IC50 = 100 μg/ml (216 μM)] acids from Tricalysia niamnia

APA, Harvard, Vancouver, ISO, and other styles

9

Goldenberg, Seth J., Jeffrey G. Marblestone, Michael R. Mattern, and Benjamin Nicholson. "Strategies for the identification of ubiquitin ligase inhibitors." Biochemical Society Transactions 38, no. 1 (2010): 132–36. http://dx.doi.org/10.1042/bst0380132.

Full text

Abstract:

Dysregulation of the UPS (ubiquitin–proteasome system) has been implicated in a wide range of pathologies including cancer, neurodegeneration and viral infection. Inhibiting the proteasome has been shown to be an effective therapeutic strategy in humans; however, toxicity with this target remains high. E3s (Ub–protein ligases) represent an alternative attractive therapeutic target in the UPS. In this paper, we will discuss current platforms that report on E3 ligase activity and can detect E3 inhibitors, and underline the advantages and disadvantages of each approach.

APA, Harvard, Vancouver, ISO, and other styles

10

Mills, Scott D., Ann E. Eakin, Ed T. Buurman, et al. "Novel Bacterial NAD+-Dependent DNA Ligase Inhibitors with Broad-Spectrum Activity and Antibacterial EfficacyIn Vivo." Antimicrobial Agents and Chemotherapy 55, no. 3 (2010): 1088–96. http://dx.doi.org/10.1128/aac.01181-10.

Full text

Abstract:

ABSTRACTDNA ligases are indispensable enzymes playing a critical role in DNA replication, recombination, and repair in all living organisms. Bacterial NAD+-dependent DNA ligase (LigA) was evaluated for its potential as a broad-spectrum antibacterial target. A novel class of substituted adenosine analogs was discovered by target-based high-throughput screening (HTS), and these compounds were optimized to render them more effective and selective inhibitors of LigA. The adenosine analogs inhibited the LigA activities ofEscherichia coli,Haemophilus influenzae,Mycoplasma pneumoniae,Streptococcus pn

APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Ligase I Inhibitors"

1

Dickens, Michael. "Small molecule inhibitors of Mdm2 E3 ubiquitin ligase activity." Thesis, University of Nottingham, 2011. http://eprints.nottingham.ac.uk/11960/.

Full text

Abstract:

Half of cancers retain wild type p53 but have alterations in the pathways involved in p53 regulation. Murine double minute 2 (Mdm2) regulates p53 by acting as an E3 ubiquitin ligase, which tags p53 for degradation through the proteasome. A small molecule inhibitor, a 5-deazaflavin analogue, has previously been identified by high throughput screening to inhibit Mdm2 E3 ubiquitin ligase activity, thereby reactivating apoptotic function of p53 selectively in cancer cells. Ninety 5-deazaflavin analogues have been synthesised by an optimized existing method and a novel method of synthesis, using th

APA, Harvard, Vancouver, ISO, and other styles

2

Cressina, Elena. "Inhibitors for the tRNA dependent ligase MurM from streptococcus pneumoniae." Thesis, University of Warwick, 2007. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.491471.

Full text

Abstract:

The FemABX family of peptide ligases comprises enzymes responsible for the branching of peptidoglycan peptide part. In particular, MurM from the bacterium S. pneu11loniae is responsible for the transfer of L-alanine or L-serine from tRNA to the lysine side chain of the peptidoglycan precursor Lipid 2. MurM, and the members of the FemABX family, have been proven by genetic experiments to be essential for the development of antibiotic resistance in pathogenic bacteria and in some cases for the life of the cell itself, and therefore they constitute a new range of targets for the development of na

APA, Harvard, Vancouver, ISO, and other styles

3

Besong, Gilbert Ebai. "Design and synthesis of D-Ala-D-Ala ligase inhibitors as novel antibacterials." Thesis, University of Leeds, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.414211.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Liu, Ran. "Design, Synthesis and Testing of Novel Small Molecule Inhibitors of S-phase Kinase-Associated Protein 2." Thesis, The University of Sydney, 2019. http://hdl.handle.net/2123/20999.

Full text

Abstract:

S-Phase Kinase-Associated Protein 2 (Skp2), an oncoprotein, is overexpressed in numerous human cancers and plays a critical role in cell cycle progression, senescence, metabolism, cancer progression and metastasis, through promoting the ubiquitination of regulatory protein substrates, such as p27KIP1, and targeting them for degradation by the 26S proteasome. Increased expression of Skp2, accompanied by decreased levels of p27KIP1, is often associated with an aggressive phenotype and poor prognosis in many cancers. This project aimed to develop small molecules which disrupt the ubiquitination l

APA, Harvard, Vancouver, ISO, and other styles

5

Brusa, Irene <1991&gt. "Design and synthesis of E3 ligase RNF5 inhibitors as innovative strategy to trigger mutant CFTR rescue in Cystic Fibrosis." Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2022. http://amsdottorato.unibo.it/10241/1/Brusa_Irene_tesi.pdf.

Full text

Abstract:

In Cystic Fibrosis (CF) the deletion of phenylalanine 508 (F508del) in the CFTR anion channel is associated to misfolding and defective gating of the mutant protein. Among the known proteins involved in CFTR processing, one of the most promising drug target is the ubiquitin ligase RNF5, which normally promotes F508del-CFTR degradation. In this context, a small molecule RNF5 inhibitor is expected to chemically mimic a condition of RNF5 silencing, thus preventing mutant CFTR degradation and causing its stabilization and plasma membrane trafficking. Hence, by exploiting a virtual screening (VS) c

APA, Harvard, Vancouver, ISO, and other styles

6

Shouksmith, Andrew Eric. "Design and synthesis of small-molecule inhibitors targeting the SCFskp2 E3 ligase and the MDMX-p53 interaction for cancer therapy." Thesis, University of Newcastle upon Tyne, 2014. http://hdl.handle.net/10443/2904.

Full text

Abstract:

The SKP1-Cullin1-F-box (SCF) E3 ligases promote the ubiquitination and proteasomemediated degradation of regulatory proteins. Subunits of the SCF complex have shown oncogenic activity, including the F-box protein S-phase Kinase-associated Protein 2 (SKP2). The SCFSKP2 E3 ligase targets several cell cycle negative regulators, e.g. p27, enabling replicative immortality. The only marketed drug that targets the ubiquitinproteasome system is Bortezomib (Velcade; Millenium Pharmaceuticals) (15), which is used to treat multiple myeloma, but has numerous side effects, as the result of targeting a prot

APA, Harvard, Vancouver, ISO, and other styles

7

SABBIONI, SIMONE. "CHARACTERIZATION OF THE MOLECULAR MECHANISM RESPONSIBLE FOR THE LOSS OF THE TUMOR SUPPRESSOR NUMB IN BREAST CANCER." Doctoral thesis, Università degli Studi di Milano, 2019. http://hdl.handle.net/2434/609517.

Full text

Abstract:

The tumor suppressor protein, Numb, safeguards against the emergence of cancer stem cells (CSCs) in the mammary gland by ensuring homeostasis of the stem cell (SC) compartment and proper progenitor maturation. Upon its downregulation, expansion of the mammary SC compartment accompanied by the acquisition of tumorigenic potential ensues, highlighting the potent tumor suppressor function of Numb in breast cancer. Indeed, Numb loss occurs in ~30% of human breast cancers and correlates with biological aggressiveness and poor prognosis. Notably, restoration of Numb expression curbs tumorigenic pote

APA, Harvard, Vancouver, ISO, and other styles

8

Gutierrez, Jemy A. "Inhibition and functional characterization of asparagine synthetase." [Gainesville, Fla.] : University of Florida, 2006. http://purl.fcla.edu/fcla/etd/UFE0015619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kaur, Loveleen. "Developing as assay to screen inhibitors for various ATP-dependent ligases." Thesis, University of Westminster, 2009. https://westminsterresearch.westminster.ac.uk/item/90xxw/developing-as-assay-to-screen-inhibitors-for-various-atp-dependent-ligases.

Full text

Abstract:

DNA ligases (EC.6.5.1.1) are key enzymes that catalyze the formation of phosphodiester bonds at single-stranded or double-stranded breaks between adjacent 5’-PO4 and 3’-OH groups of DNA. These enzymes are essential guardians of genomic integrity and have recently been drawing a lot of attention as novel therapeutic targets in anti-bacterial and anticancer therapies. A novel, non-electrophoretic assay method, based on the strength of interaction of the oligonucleotides with Q-sepharose (a strong anion exchanger), was developed to screen inhibitors of DNA ligases from natural product pools as we

APA, Harvard, Vancouver, ISO, and other styles

10

Chobotova, Katya. "Ligand binding determinants of LIF receptor." Thesis, University of Oxford, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.244596.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Ligase I Inhibitors"

1

Helmsen, Sabine. Protein-Ligand-, Protein-Inhibitor- und Protein-Protein-Wechselwirkungen. Springer Fachmedien Wiesbaden, 2020. http://dx.doi.org/10.1007/978-3-658-30151-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hyŏmnyŏktan, Koryŏ Taehakkyo Sanhak. E3, ubiquitin ligase chŏhaeje rŭl wihan E1-E2-E3-substrate cognate pair network chŏngnip kisul kaebal kwa i rŭl iyong han tanangsŏng sinjŭnghugun (ADPKD) ch'iryoje kaebal yŏn'gu =: Study on E1-E2-E3-substrate cognate pair network for E3 ligase inhibitor and application. Pogŏn Pokchi kajokpu, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

J, Beuth, and Pulverer Gerhard, eds. Lectin blocking: New strategies for the prevention and therapy of tumor metastasis and infectious diseases : proceedings of the Intern. Symposium Otzenhausen, May 8-9, 1993. Fischer, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Stefanis, Leonidas, and J. N. Keller. Proteasome in Neurodegeneration. Springer London, Limited, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

(Editor), Leonidas Stefanis, and J. N. Keller (Editor), eds. The Proteasome in Neurodegeneration. Springer, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Rashwan, Hesham. Studies on inhibition of GMP synthetase and MTA phosphorylase. 1986.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Helmsen, Sabine. Protein-Ligand-, Protein-Inhibitor- und Protein-Protein-Wechselwirkungen: Einsatz analytischer Methoden zu deren Bestimmung. Springer Spektrum, 2020.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Ligase I Inhibitors"

1

Mattern, Michael R., Michael J. Eddins, Saket Agarwal, et al. "Proteasome Inhibitors Versus E3 Ligase Inhibitors for Cancer Therapy." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06752-0_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Fu, Xiaoli, Jie Chu, Yuyin Li, et al. "Design, Synthesis, and Biological Evaluation of Nedd4 E3 Ubiquitin Ligase Small Molecule Inhibitors." In Proceedings of the 2012 International Conference on Applied Biotechnology (ICAB 2012). Springer Berlin Heidelberg, 2013. http://dx.doi.org/10.1007/978-3-642-37925-3_195.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Martin, David P., David T. Puerta, and Seth M. Cohen. "Metalloprotein Inhibitors." In Ligand Design in Medicinal Inorganic Chemistry. John Wiley & Sons, Ltd, 2014. http://dx.doi.org/10.1002/9781118697191.ch14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Sayers, Thomas J. "TNF-Related Apoptosis-Inducing Ligand (TRAIL)." In Proteasome Inhibitors in Cancer Therapy. Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-794-9_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kos, J., V. Arbanas, V. Turk, and A. V. Maksimenko. "Chicken egg white cystatin as a ligand for affinity chromatography." In Cysteine Proteinases and their Inhibitors, edited by Vito Turk. De Gruyter, 1986. http://dx.doi.org/10.1515/9783110846836-053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Liang, Shuguang, Wei Xu, Kurumi Y. Horiuchi, Yuan Wang, and Haiching Ma. "Chemical Microarrays: A New Tool for Discovery Enzyme Inhibitors." In Ligand-Macromolecular Interactions in Drug Discovery. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60761-244-5_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Watanabe, Nobumoto, and Hiroyuki Osada. "CHAPTER 5. Small Molecule Inhibitors of E3 Ubiquitin Ligases." In Protein–Protein Interaction Regulators. Royal Society of Chemistry, 2020. http://dx.doi.org/10.1039/9781788016544-00109.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Helmsen, Sabine. "Einleitung und Zielsetzung." In Protein-Ligand-, Protein-Inhibitor- und Protein-Protein-Wechselwirkungen. Springer Fachmedien Wiesbaden, 2020. http://dx.doi.org/10.1007/978-3-658-30151-4_1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Helmsen, Sabine. "Theoretischer Hintergrund." In Protein-Ligand-, Protein-Inhibitor- und Protein-Protein-Wechselwirkungen. Springer Fachmedien Wiesbaden, 2020. http://dx.doi.org/10.1007/978-3-658-30151-4_2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Helmsen, Sabine. "Praktische Arbeiten." In Protein-Ligand-, Protein-Inhibitor- und Protein-Protein-Wechselwirkungen. Springer Fachmedien Wiesbaden, 2020. http://dx.doi.org/10.1007/978-3-658-30151-4_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Ligase I Inhibitors"

1

Scotti, Francesca, Sanjib Bhakta, and John P. Malkinson. "Lasso Peptides and Murein Peptide Ligase Inhibitors as Novel Anti-Mycobacterial Agents." In The 24th American Peptide Symposium. Prompt Scientific Publishing, 2015. http://dx.doi.org/10.17952/24aps.2015.193.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Shukla, Shirish, Qingjie Zhao, Weijang Ying, et al. "Abstract 3520: Small molecule inhibitors of ring1B-Bmi1 E3 ligase target polycomb repressive complex 1 activity and regulate cell proliferation." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3520.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Tseng, Hui-Min, David Shum, Hakim Djaballah, and David Scheinberg. "Abstract 3689: Identification of DNA ligase IV inhibitors as possible drug and probe candidates for enhancement of radiation treatment and chemotherapy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3689.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Li, Hua, Elizabeth Umeda, Yingjie Song, et al. "Abstract 4679: Silencing of PMEPA1, a NEDD4 E3 ubiquitin ligase binding protein, stabilizes androgen receptor and confers resistance to AR inhibitors." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-4679.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Daubriac, Julien, Jonathan Melamed, Unnati Pandya, Harvey I. Pass, and Leslie I. Gold. "Abstract LB-068: Inhibitors of Skp2 E3 ligase-mediated degradation of p27kip1 as a novel therapeutic approach to malignant pleural mesothelioma." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-lb-068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Egbuta, Chinaza, Julien Dubrulle, Ana Tellechea, et al. "Abstract 5231: Small-molecule inhibitors of SCF-Skp2-Cks1 ubiquitin E3 ligase stabilize nuclear p27kip1as a novel therapeutic approach to endometrial cancer." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-5231.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sosin, Angela M., Angelika M. Burger, Dajun Yang, Ramzi M. Mohammad, and Ayad Al-Katib. "Abstract 4516: A new class of MDM2 inhibitors cause growth inhibition and stabilize wt p53 in lymphoma cells but do not interfere with MDM2 E3 ligase activity." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4516.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Kheraldine, Hadeel, Ishita Gupta, Farhan Cyprian, Semir Vranic, and Ala-Eddin Al Moustafa. "The Combination of Dasatinib and PD L1 inhibitor prevents the progression of epithelial mesenchymal transition and dramatically blocks cell invasion of HER2 positive breast cancer cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0105.

Full text

Abstract:

Introduction: Both Dasatinib (DA), a tyrosine kinase inhibitor that is used for targeted cancer therapy, and programmed death-ligand 1 (PD-1/PD-L1) inhibitor that is an immune checkpoint therapy, play a vital role in the management of several types of solid tumors, including breast. Nevertheless, the combined outcome of DA and PD-1/PD-L1 inhibitors in human carcinomas has not been explored yet. Materials and methods: We herein compared the individual impact of DA and PD-1/PD-L1 inhibitors (BMS-202) with their combination on two human HER2-positive breast cancer cell lines, SKBR3 and ZR75. Resu

APA, Harvard, Vancouver, ISO, and other styles

9

Mitsuuchi, Yasuhiro, Christopher A. Benetatos, Thomas Haimowitz, et al. "Abstract 1806: Birinapant, a bivalent SMAC-mimetic, promotes efficient cellular IAP E3 ligase activity and formation of a pro-apoptotic RIPK1:caspase-8 complex while monovalent IAP inhibitors are less efficient - implications for therapeutic utility." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1806.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Duckworth, Benjamin P., Helena I. Boshoff, Clifton E. Barry, and Courtney C. Aldrich. "Design of a nucleoside inhibitor of biotin protein ligase from Mycobacterium tuberculosis." In XVth Symposium on Chemistry of Nucleic Acid Components. Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, 2011. http://dx.doi.org/10.1135/css201112199.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Ligase I Inhibitors"

1

Guo, Lijuan, Xiaoyi Lin, Xin Lin, et al. Risk of Interstitial Lung Disease With Use of Programmed Cell Death 1 Inhibitors versus Programmed Cell Death Ligand 1 Inhibitors In Breast Cancer: A meta-analysis and Cases description. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.6.0007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Matsuyama, Shigemi. Apoptosis Induction by Targeting Interferon Gamma Receptor 2 (IFNgammaR2) in Prostate Cancer: Ligand (IFNgamma)-Independent Novel Function of IFNgammaR2 as a Bax Inhibitor. Defense Technical Information Center, 2014. http://dx.doi.org/10.21236/ada611816.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Matsuyama, Shigemi. Apoptosis Induction by Targeting Interferon Gamma Receptor 2 (IFNgammaR2) in Prostate Cancer: Ligand (IFNgamma)-Independent Novel Function of IFNgammaR2 as a Bax Inhibitor. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada591011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Matsuyama, Shigemi. Apoptosis Induction by Targeting Interferon Gamma Receptor 2 (IFNgammaR2) in Prostate Cancer: Ligand (IFNgamma)-Independent Novel Function of IFNgammaR2 as a Bax Inhibitor. Defense Technical Information Center, 2015. http://dx.doi.org/10.21236/ada623598.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Liu, Shu, Xin Zhang, Wenhan Yang, and Shun Xu. Association of Patient Sex with Efficacy of Programmed Death-1/Ligand-1 Inhibitors in Advanced Non–small-cell Lung Cancer: A Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.1.0005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Altstein, Miriam, and Ronald J. Nachman. Rational Design of Insect Control Agent Prototypes Based on Pyrokinin/PBAN Neuropeptide Antagonists. United States Department of Agriculture, 2013. http://dx.doi.org/10.32747/2013.7593398.bard.

Full text

Abstract:

The general objective of this study was to develop rationally designed mimetic antagonists (and agonists) of the PK/PBAN Np class with enhanced bio-stability and bioavailability as prototypes for effective and environmentally friendly pest insect management agents. The PK/PBAN family is a multifunctional group of Nps that mediates key functions in insects (sex pheromone biosynthesis, cuticular melanization, myotropic activity, diapause and pupal development) and is, therefore, of high scientific and applied interest. The objectives of the current study were: (i) to identify an antagonist bioph

APA, Harvard, Vancouver, ISO, and other styles

7

Altstein, Miriam, and Ronald Nachman. Rationally designed insect neuropeptide agonists and antagonists: application for the characterization of the pyrokinin/Pban mechanisms of action in insects. United States Department of Agriculture, 2006. http://dx.doi.org/10.32747/2006.7587235.bard.

Full text

Abstract:

The general objective of this BARD project focused on rationally designed insect neuropeptide (NP) agonists and antagonists, their application for the characterization of the mechanisms of action of the pyrokinin/PBAN (PK-PBAN) family and the development of biostable, bioavailable versions that can provide the basis for development of novel, environmentally-friendly pest insect control agents. The specific objectives of the study, as originally proposed, were to: (i) Test stimulatory potencies of rationally designed backbone cyclic (BBC) peptides on pheromonotropic, melanotropic, myotropic and

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!